When he took over, DePuy, the firm’s orthopedic unit was already running into trouble with its newest artificial hip.it was facing resistance from the Food and Drug administration even as complaints about the device were mounting from doctors and regulators around the world. Gorsky moved quickly to phase out the defective hip replacements, although he did not publicly disclose the problem that it had been experiencing with the FDA over the sale of these . the decision not to publicize the agency’s finding to doctors, patients, and others while continuing to market the device has exposed Johnson to the lawsuits that can tarnish its reputation